February 19, 2017 9:33 PM ET

Healthcare Equipment and Supplies

Company Overview of AxoGen, Inc.

Company Overview

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf human nerve allograft for bridging nerve discontinuities without the comorbidities associated with another surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue atta...

13631 Progress Boulevard

Suite 400

Alachua, FL 32615

United States

113 Employees





Key Executives for AxoGen, Inc.

Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $511.0K
Senior Vice President of Business Development, General Counsel and Director
Age: 54
Total Annual Compensation: $303.0K
Senior Vice President of Sales
Age: 58
Total Annual Compensation: $374.3K
Compensation as of Fiscal Year 2015.

AxoGen, Inc. Key Developments

AxoGen, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-15-2017 01:30 PM

AxoGen, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-15-2017 01:30 PM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States.

AxoGen, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2016; Reiterates 2017 Annual Revenue

AxoGen, Inc. provided preliminary unaudited earnings guidance for the fourth quarter and full year ended December 31, 2016. Fourth quarter revenue is expected to be at least $11.3 million, up 45% compared to the fourth quarter of 2015 revenue of $7.8 million. Full year 2016 revenue is expected to be at least $41.0 million, up 50% compared to 2015 revenue of $27.3 million. Management increases its full year 2016 revenue guidance to at least $41.0 million from its previous estimate of over $40.0 million. Management reiterates its full year 2016 gross margin guidance to exceed 80%. Management reiterates 2017 annual revenue will grow at least 40% over 2016 revenue and gross margins will remain above 80%.

AxoGen, Inc. Appoints Ivica (Ivan) Ducic as Medical Director of Clinical and Translational Sciences

AxoGen, Inc. announced the appointment of Ivica (Ivan) Ducic, M.D., Ph.D. as Medical Director of Clinical and Translational Sciences. Dr. Ducic will be responsible for AxoGen's global medical affairs programs as a non-officer member of the leadership team. Dr. Ducic is the past president of American Society for Peripheral Nerve.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AxoGen, Inc., please visit www.axogeninc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.